Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 4;49(2):0300060520986049. doi: 10.1177/0300060520986049

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 5. — The sirtuin-1 (SIRT1) activator SRT2104 suppresses p53 expression and rescues FOXO3a expression in cigarette smoke-media suspension (CSM)-treated type II alveolar epithelial cells (AECIIs). The AECIIs were treated with SRT2104 and then stimulated with 10% CSM for 24 hours. Total RNA was isolated, and the mRNA levels of SIRT1, forkhead box O3a (FoxO3a), p53, p21, matrix metalloprotease (MMP)-9, and tissue inhibitor of metalloprotease (TIMP)-1 were assessed by quantitative real-time PCR. Data represent the means ± standard deviations of three samples from a single experiment representative of three independent experiments. *p < 0.05 vs. senescent AECIIs. Groups: A (AECII control group), B (senescent AECII group), C (SIRT1 selective agonist SRT2104 group) and D (LV-SAL-RNA1 transduction group).